Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms

Experimental Hematology

Volumn 41, Issue 3, 2013, Pages

  Gao, Shen meng ^a   Chen, Chi qi ^a   Wang, Lu yao ^a   Hong, Li li ^a   Wu, Jian bo ^a   Dong, Pei hong ^a   Yu, Fu jun ^a  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYRIC ACID; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE INHIBITOR; JANUS KINASE 2; MESSENGER RNA; STAT PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3;

ARTICLE; BURST FORMING UNIT E; CANCER INHIBITION; COLONY FORMING UNIT GM; CONTROLLED STUDY; GENE EXPRESSION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; MONONUCLEAR CELL; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION; THROMBOTIC THROMBOCYTOPENIC PURPURA; UPREGULATION;

EID: 84874985575     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2012.10.012     Document Type: Article

References (29)

1. Nosaka T., Kitamura T. Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) in hematopoietic cells. Int J Hematol 2000, 71:309-319.
2. Walz C., Ahmed W., Lazarides K., et al. Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and Jak2V617F in mice. Blood 2012, 119:3550-3560.
3. James C., Ugo V., Le Couedic J.P., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144-1148.
4. Tefferi A. JAK2 mutations in polycythemia vera-molecular mechanisms and clinical applications. N Engl J Med 2007, 356:444-445.
5. Teofili L., Martini M., Cenci T., et al. Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation. Blood 2007, 110:354-359.
6. Hart S., Goh K.C., Novotny-Diermayr V., et al. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia 2011, 25:1751-1759.
7. Constantinescu S.N., Girardot M., Pecquet C. Mining for JAK-STAT mutations in cancer. Trends Biochem Sci 2008, 33:122-131.
8. Russell R.C., Sufan R.I., Zhou B., et al. Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia. Nat Med 2011, 17:845-853.
9. Ungureanu D., Saharinen P., Junttila I., Hilton D.J., Silvennoinen O. Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1. Mol Cell Biol 2002, 22:3316-3326.
10. Haan S., Wuller S., Kaczor J., et al. SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling. Oncogene 2009, 28:3069-3080.
11. Iacobuzio-Donahue C.A. Epigenetic changes in cancer. Annu Rev Pathol 2009, 4:229-249.
12. Delcuve G.P., Khan D.H., Davie J.R. Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors. Clin Epigenetics 2012, 4:5.
13. Wang J.C., Chen C., Dumlao T., et al. Enhanced histone deacetylase enzyme activity in primary myelofibrosis. Leuk Lymphoma 2008, 49:2321-2327.
14. Skov V., Larsen T.S., Thomassen M., et al. Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms. Leuk Lymphoma 2012, 53:123-129.
15. Marks P.A. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs 2010, 19:1049-1066.
16. Xiong H., Du W., Zhang Y.J., et al. Trichostatin A, a histone deacetylase inhibitor, suppresses JAK2/STAT3 signaling via inducing the promoter-associated histone acetylation of SOCS1 and SOCS3 in human colorectal cancer cells. Mol Carcinog 2012, 51:174-184.
17. Wang Y., Fiskus W., Chong D.G., et al. Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood 2009, 114:5024-5033.
18. Guerini V., Barbui V., Spinelli O., et al. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia 2008, 22:740-747.
19. Akada H., Akada S., Gajra A., et al. Efficacy of vorinostat in a murine model of polycythemia vera. Blood 2012, 119:3779-3789.
20. Tsai H.C., Baylin S.B. Cancer epigenetics: linking basic biology to clinical medicine. Cell Res 2011, 21:502-517.
21. DeAngelo Daniel J., Fiskus Warren, Mesa Ruben A., et al. A phase II trial of panobinostat, an orally available deacetylase inhibitor (DACi), in patients with primary myelofibrosis (PMF), post essential thrombocythemia (ET), and post polycythemia vera (PV) myelofibrosis. Blood 2010, 116. (ASH Annual Meeting Abstracts).
22. Rambaldi A., Dellacasa C.M., Finazzi G., et al. A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol 2010, 150:446-455.
23. Marubayashi S., Koppikar P., Taldone T., et al. HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. J Clin Invest 2010, 120:3578-3593.
24. Wang Y., Wang S.Y., Zhang X.H., et al. FK228 inhibits Hsp90 chaperone function in K562 cells via hyperacetylation of Hsp70. Biochem Biophys Res Commun 2007, 356:998-1003.
25. Rahmani M., Yu C., Dai Y., et al. Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. Cancer Res 2003, 63:8420-8427.
26. Krennhrubec K., Marshall B.L., Hedglin M., Verdin E., Ulrich S.M. Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors. Bioorg Med Chem Lett 2007, 17:2874-2878.
27. Yan W., Liu S., Xu E., Zhang J., Zhang Y., Chen X. Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8. Oncogene 2012, in press.
28. Balasubramanian S., Ramos J., Luo W., Sirisawad M., Verner E., Buggy J.J. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia 2008, 22:1026-1034.
29. Oehme I., Deubzer H.E., Wegener D., et al. Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res 2009, 15:91-99.